化合物PFK-015 T2455

Product Introduction
Bioactivity


英文名: PFK-015

描述: PFK-015 (PFK15) 是一种有效的 PFKFB3 抑制剂，对重组PFKFB3的IC50为110 nM。它能抑制 Y 细胞中的 PFKFB3 活性，IC50为20 nM。

细胞实验: Viability is determined using trypan blue exclusion. Cells were incubated in 20% trypan blue for 5 minutes. Cells excluding trypan blue are counted using a standard hemocytometer to determine the total number of viable cells. Experiments are conducted in triplicate. (Only for Reference)

激酶实验: Recombinant PFKFB3 assay: Kinase reactions are conducted by incubating 13 ng of recombinant human PFKFB3 protein in a reaction mix containing 10 μmol/L ATP, 10 μmol/L F6P, and either dimethyl sulfoxide (DMSO) vehicle control, 3PO, or PFK15 for 1 hour at room temperature. Kinase activity is measured with the Adapta Universal Kinase Assay per manufacturer

体外活性: PFK-015（25 mg/kg,i.p.）对同源小鼠体内LLC肿瘤的生长、转移扩散及葡萄糖代谢具有抑制作用.在三个人异种移植的无胸腺癌症小鼠模型中,PFK-015与公认化疗药物的抗癌效果相似.PFK-015有适当的体内药代动力学性质.

体内活性: 在Jurkat T-细胞白血病细胞和H522肺腺癌细胞中,PFK-015可使F26BP、葡萄糖摄取及细胞内腺嘌呤核苷三磷酸水平降低。PFK-015还对一系列癌细胞的生长具有明显的抑制作用。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 26 mg/mL (100 mM)


关键字: Autophagy | PFK-15 | 3PO | stomach cancer | cancers | inhibit | PFK 15 | PFKFB3 | esophageal squamous cell carcinoma (ESCC) | PFK015 | lung cancer | colon cancer | Inhibitor | PFK-015

相关产品: Dorzagliatin | KDM4-IN-2 | ML251 | (E)-3PO | Cefetrizole | AP-III-a4 | PF-04937319 | PFKFB3-IN-2 | PFK-158 | Kaempferitrin

相关库: Anti-Aging Compound Library | Anti-Cancer Metabolism Compound Library | ReFRAME Related Library | Anti-Metabolism Disease Compound Library | Inhibitor Library | Kinase Inhibitor Library | Metabolism Compound Library | Target-Focused Phenotypic Screening Library | Glycolysis Compound Library | NO PAINS Compound Library

化合物PFK-015 T2455信息由TargetMol中国为您提供，如您想了解更多关于化合物PFK-015 T2455报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途